TERT promoter alterations could provide a solution for Peto’s paradox in rodents by Vedelek, Balázs et al.
1
Vol.:(0123456789)
Scientific Reports |        (2020) 10:20815  | https://doi.org/10.1038/s41598-020-77648-0
www.nature.com/scientificreports
TERT promoter alterations could 
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Cancer is a genetic disease caused by changes in gene expression resulting from somatic mutations 
and epigenetic changes. Although the probability of mutations is proportional with cell number and 
replication cycles, large bodied species do not develop cancer more frequently than smaller ones. 
This notion is known as Peto’s paradox, and assumes stronger tumor suppression in larger animals. 
One of the possible tumor suppressor mechanisms involved could be replicative senescence caused 
by telomere shortening in the absence of telomerase activity. We analysed telomerase promoter 
activity and transcription factor binding in mammals to identify the key element of telomerase gene 
inactivation. We found that the GABPA transcription factor plays a key role in TERT regulation in 
somatic cells of small rodents, but its binding site is absent in larger beavers. Protein binding and 
reporter gene assays verify different use of this site in different species. The presence or absence of 
the GABPA TF site in TERT promoters of rodents correlates with TERT promoter activity; thus it could 
determine whether replicative senescence plays a tumor suppressor role in these species, which could 
be in direct relation with body mass. The GABPA TF binding sites that contribute to TERT activity in 
somatic cells of rodents are analogous to those mutated in human tumors, which activate telomerase 
by a non-ALT mechanism.
It has been observed that between different species, animal body size and cancer incidence do not correlate with 
each other, despite the fact that larger biomasses are assembled from more cells and would, therefore, be expected 
to incur an increased probability of  mutations1. Within species, however, the incidence of cancer is higher in 
larger  individuals2. To explain this contradiction it was suggested that animal species with larger bodies have 
developed more strict tumor suppressor mechanisms than those with smaller  ones3,4. One of these mechanisms is 
the regulation of telomere length through telomerase reverse transcriptase (TERT) enzyme  activity5–9. In human 
stem cells the telomerase is active, however in somatic cells the catalytic subunit of the enzyme is transcriptionally 
 silenced10. In the absence of functional telomerase, chromosome ends shorten with each cell cycle as a result of 
the end replication  problem11,12. Depleted telomeres induce apoptosis or cause cell cycle arrest, resulting in a cell 
state referred to as replicative senescence. The tumor suppressor role of replicative senescence is still debated, 
however it is supported by numerous wet lab  experiments8,13–16  (see9 for a review). A recent report on whole 
genome sequence analysis of a very large number of tumor samples also strengthens the tumor suppressor role 
of senescence induced by telomere  attrition17. The reason for the debate concerning the tumor suppressor role 
of replicative senescence is its similarity to induced senescence, which occurs from causes other than telomere 
shortening in cellular homeostasis during ageing of cells. With certain limitations induced senescence can be 
considered a tumor suppressor  mechanism18; however, it is a “double-edged sword” since senescent cells could 
both improve immune response and promote tumor progression—for reviews on this  see19,20.
In somatic cells of mice and other small rodents the TERT promoter is  active21. In these rodents, the tumor 
suppressor effect of telomere shortening may never be essential or take place because their lifespan is short and 
fewer number of cell divisions are necessary to reach the final body mass compared to large  mammals6,7. In 
general, in mammalian species the length of telomeres in somatic cells is in correlation with telomerase activ-
ity and inversely correlates with body mass, but not with  lifespan6,7,22. Nevertheless diverse tumor suppressor 
mechanisms act in small but long lived animals, like naked mole rats or  squirrels23.
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Replicative senescence resulting from telomere shortening is the consequence of telomerase inactivation in 
somatic cells. Early experiments with TERT null mutant mice resulted in contradicting data regarding the tumor 
suppressor effect of telomere shortening. In the absence of TERT expression telomeres indeed shortened in mice, 
but the overall tumor incidence  increased24. However, telomere depleted mice were resistant to skin  cancer25. 
The increased cancer incidence in TERT KO mice could be explained by telomere loss in stem cells compromis-
ing the immune system, thereby allowing more cancer cells to avoid immune surveillance. Several other severe 
phenotypes characterize TERT KO mice, indicating the importance of telomere maintenance in stem  cells26. A 
recent report offers further insight to this puzzle by pointing out the importance of transient upregulation of 
TERT for appropriate senescence  response27. It was found that cells from animals in which the telomere length 
was shortened due to down-regulation of TERT reached senescence earlier than cells from their wild type rela-
tives; however, a transient TERT up-regulation was necessary for the proper senescence response. Without TERT, 
cells were more frequently immortalized using the alternative telomere elongation (ALT) mechanism, which 
caused increased tumor incidence. In contrast, when TERT gene was present, fewer cells were immortalized 
due to the proper senescence response. Cells only occasionally escaped from senescence, which was associated 
with telomerase activation. Only 10% of human tumors maintain telomeres by ALT and 90% use reactivation of 
TERT, which reveals the importance of replicative senescence in tumor  suppression28–31.
During the evolution of rodents the inactivation and activation of telomerase in somatic cells may have hap-
pened multiple times. Telomerase in platypus is found to be  active32. It is believed that it became inactivated in 
early placental mammals but reactivated in a common ancestor of rodents, and it is active in most recent rodent 
 species6,22. Exceptions are beavers and capybaras, in which the telomerase activity is lower than in other rodents. 
These species have larger body masses, at which replicative senescence could be beneficial. We hypothesized that 
telomerase inactivation in beavers and capybaras originates from changes in the promoter of the TERT gene. 
Revealing the importance of a cis-acting element in TERT gene inactivation highlights not only an evolutionary 
mechanism that allowed longevity and therefore increased fitness of large bodied animals, but also our vulner-
ability to acquired mutations providing an ideal cellular environment for the development of cancer.
Due to the rapid development of sequencing methods, genome sequence data are available from a wide vari-
ety of mammals. By using these and data on telomerase activity, it is possible to identify potential transcription 
factor binding sites that could explain the activation or inactivation of TERT expression in different mammals. 
By identifying these transcription factors, a mechanism can be proposed to explain the evolution of replicative 
senescence as a tumor suppressor mechanism in larger animals.
In this study we performed comparative TERT promoter analysis of different mammals with known TERT 
activity in somatic cells. We found that GABPA is a key factor in determining TERT transcription status in mam-
mals of different evolutionary groups, similarly to certain human cancer cells. Our results support the hypothesis 
that a mutation in the TERT promoter is sufficient for the inactivation of the gene in somatic cells, triggering 
replicative senescence as a tumor suppressor mechanism. Therefore, the presence or absence of the GABPA 
binding site in the TERT promoter depicts a mechanism that might solve Peto’s paradox.
Results
GABPA, Elk1, E47 and GATA3 binding sites represent differences between active and inactive 
TERT promoters. To study the promoter regions of the TERT gene we extracted 1000 bp long sequences 
upstream from the TERT start codon of 28 placental mammalian species from public databases. In 14 of these 
species telomerase is active, while in the rest telomerase is inactive in somatic cells. Data on telomerase activ-
ity were collected from the literature, and reflect mainly TERT activity determined in fibroblasts from skin, 
kidney, lung or  cornea6,7,22,32–34. An alignment of the sequences reveals that the TERT promoter sequence is rap-
idly evolving, therefore a comparison among them on nucleic acid level is challenging (Supplementary Fig S1). 
However, transcription factor (TF) binding sites are more conserved. To identify and compare TF sites within 
these promoter regions we analysed the sequences by Match and TFbind  software35. The identified TF bind-
ing sites were scored based on their similarity to the consensus site matrices and filtered based on their score. 
Strong binding motifs that ranked above cut-off values were considered in further analysis. The frequency of pre-
dicted TF binding sites was summarised and analysed by random-sampling bootstrap method (Supplementary 
Table S1). In cases where binding sites showed near binary distribution we also performed Fisher’s exact tests 
(Supplementary Table S2). The transcription factor matrices, which were identified by at least two prediction 
methods or statistical probes, are summarised in Table 1.
By the analysis described above, we identified four factors that could have a role in the different regulation of 
the TERT gene in small and large-bodied mammals. The GABPA (or NRF2) and ELK1 proteins are Ets transcrip-
tion factor family members. E47 (or TCF3) is a member of the E protein family of helix-loop-helix transcription 
factors, and GATA3 is a member of the GATA transcription factor family. The E47 (V$E47_01) binding site is 
more likely to be present in inactive TERT promoters, while the other three sites (V$NRF2_01, V$Elk1_02, 
V$GATA3_01) are mostly found on active promoters. We performed k-means clustering multiple times on the 
data using the occurrence of transcription factors and the telomere state as a base. The clustering which best 
represents phylogenetic relations is presented in Fig. 1. (Other possible clusterings are listed in Supplementary 
Table S3). In groups I and II the telomerase is inactive; NRF2 and ELK1 sites are absent, but E47 binding sites 
are present. In group III the telomerase is inactive despite the presence of ELK1 and GATA3 sites. Group IV is 
characterized by active telomerase and the presence of GATA3 transcription factor sites, but no other studied 
site is present in these promoters. Telomerase is also active in group V where GABPA and ELK1 binding sites 
are present, however E47 sites are rare.
Next, we examined the positional distribution of these transcription factor binding sites on the promoter 
sequences of different species (Fig. 2). GABPA sites are located frequently between the − 150 and − 200 bp region 
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upstream of the START codon. ELK1 sites also seem to be present in this region (ELK1 is also an Ets factor with 
highly similar recognition sequence) but in a more scattered pattern. E47 sites are more often present in the 
inactive promoters, about 800 bp upstream of the START codon. GATA3 sites show an even distribution, and 
like the GABPA and Elk1 sites they can be found in active promoters.
Based on our statistics on binding site presence and binding site distribution, we concluded that the GABPA 
TF could be the distinguishing factor between TERT active and inactive states. Our conclusion is supported 
by the notion that in human tumor cells a single mutation either at 146 or at 124 nucleotides upstream of the 
START codon of TERT is enough to reactivate  telomerase29,36. C to T mutation(s) within either or both of these 
sites creates a binding site for the GABPA transcription factor. Binding of the GABP complex of GABPA and 
GABPB results in the spreading of euchromatic chromatin structure to the promoter region and consequent 
transcriptional  activation29,37.
We also tested the conservation of the GABPA protein among mammals to see the conservation of its con-
sensus binding site. We found that the protein is highly conserved, with an identical DNA binding domain in 
most cases (Supplementary Fig S2). Only mouse (Mus musculus) and shrew (Elephantulus edwardii) GABPA 
have amino acid differences in the DNA binding domain; however, based on the available 3D structures of 
GABPA-DNA interaction, these differences probably do not affect the DNA binding surface of the molecule 
(Supplementary Fig S2). Consequently, the similarity of different mammalian GABPA proteins suggests that 
their consensus recognition site is also conserved.
The presence or absence of a strong GABPA binding site determines TERT expression in 
somatic cells. Next, we searched for more direct proof on the role of GABPA at TERT promoters. For this 
we used publicly available ChIP-Seq data on GABPA localization and found that both in human and mouse 
embryonic stem cells the GABP protein complex is present on the TERT promoter (Fig. 3A). On the other hand, 
in human somatic cells in which the telomerase is inactivated, no GABPA binding is detected. ChIP-Seq data 
also demonstrate that in SK-N-SH or HEPG2 tumor cells GABPA is present at the TERT promoter region. This is 
due to consensus binding sites created by point mutations (Fig. 3B). However, in MCF-7 tumor cells no GABPA 
was detected on the TERT promoter.
According to our hypothesis, the presence or absence of GABPA binding site at the TERT promoter is the 
determining factor of telomerase expression in small-bodied rodents such as mice, versus no expression in larger-
bodied rodents such as beavers. Among the sequenced mouse genomes accessible at Sanger Centre none carries 
an SNP that would affect this GABPA binding site, indicating the strong preservation of this motif. To validate 
that GABPA binding to the TERT promoter of small rodents is indeed a characteristic of not only embryonic 
stem cells but also of somatic cells, we performed ChIP experiments in the mouse NIH 3T3 cell line, and showed 
that GABPA binds to the TERT promoter (Fig. 4A). We assume that in beavers (Castor canadensis), mutation 
of the GABPA binding site 150–200 bp upstream of the start codon inactivated TERT expression and allowed 
replicative senescence to take place. The lack of beaver cell cultures and the difficulties of obtaining biological 
samples prevented us from conducting ChIP experiments on beaver samples. However, we were able to test 
whether GABPA is able to bind to the beaver TERT promoter. Castor canadensis genomic DNA (kindly provided 
by Dr. Si Lok) was used to amplify a 500 bp fragment within the TERT promoter  region38. This promoter frag-
ment harbours a weak GABPA binding site at 164–158 bp upstream of the translation start codon. The score 
of this site, according to TFbind prediction, is below the cut-off value. We generated a strong GABPA binding 
site containing a variant of this promoter fragment (with TFbind score prediction above cut-off) by introducing 
TT > CG changes at position − 159–158 (Supplementary Fig S1). PCR-amplified 500 bp wild type and mutant 
promoter fragments were used to test their GABPA binding affinity by microscale thermophoresis (MST). For 
this, GFP-GABPA protein (Supplementary Fig S3) or fluorescently labelled DNA was used. GFP-GABPA showed 
interaction with the mutant version of the beaver promoter, while no interaction was detected with the wild type 
Table 1.  Summary of transcription factor matrices that were found to be significant by at least two 
approaches. a Probabilities for three zero hypotheses were calculated. Low values (< 0.05, bold) indicate 
hypothesis deemed to be failed.
Factor (Matrices ID) Prediction method Statistics
H0: inactive > active 
(p-value)a
H0: inactive = active 
(p-value)a




Match Bootstrap 0.0000 0.0834 0.9172
Match Fisher – 0.0002 –
TFBind Bootstrap 0.0000 0.0272 0.9710
TFBind Fisher – 0.0213 –
E47
(V$E47_01)
Match Bootstrap 0.6024 0.3866 0.0008
TFBind Bootstrap 0.9136 0.0886 0.0000
TFBind Fisher – 0.0183 –
GATA3
(V$GATA3_01)
TFBind Bootstrap 0.0008 0.2022 0.7892
TFBind Fisher – 0.0461 –
Elk1
(V$ELK1_02)
Match Bootstrap 0.0026 0.2010 0.8074
TFBind Fisher – 0.0407 –
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promoter (Fig. 4B). The reciprocal experiment with labelled DNA and non-fluorescent GABPA (Supplementary 
Fig S3) produced similar results (Fig. 4C).
Following these experiments, we intended to test the effect of GABPA binding site on the activity of different 
TERT promoters. Silencing or knocking out a general transcription factor such as GABPA would most likely 
disrupt normal cell function, and TERT expression could also be affected as an off-target effect. Instead, we 
focused specifically on the promoter regions and conducted luciferase reporter assays using human, beaver, rat 
and mouse TERT promoters in multiple cell lines to obtain conclusive data. We also generated mutant versions 
of the promoters: a GABPA binding site was introduced into human and beaver promoters (C to T at − 146 and 
see above, respectively), and GABPA binding sites were removed from the rat and mouse TERT promoters (T to 
Figure 1.  Telomerase state and transcription factor binding site distribution among 28 studied mammalian 
species. (A) The 28 species were clustered into 5 groups by k-means clustering based on predicted transcription 
factor binding sites and telomerase state (active+/inactive−). The background coloring of species names 
represents phylogenetic relations. (B) The phylogenetic relationship of the 28 species involved in the study. Red 
indicates species with active, black with inactive telomerase in somatic cells. (C) Principal component analysis 
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C at − 163 and T to C at − 162, respectively) (for the mutation sites and predicted TFbind scores of the wild type 
and constructed mutant TERT promoters see Supplementary Fig S1). Wild type and mutant TERT promoter 
fragments were inserted into pGL3Basic promoter probe vector in front of the luciferase coding sequence, and 
their activity was tested in two human (MCF-7, breast cancer; UACC-257, melanoma) and two rodent cell lines 
(D12, rat hepatocarcinoma; NIH 3T3, mouse fibroblast) by transient transfection experiments. Introduction 
of the GABPA binding site into the human and beaver promoters (GABPA +) increased the activity of these 
compared to their wild type (GABPA−) counterparts. On the other hand, mutation in the GABPA binding site 
(GABPA−) greatly decreased the activity of mouse and rat promoters compared to the activity of their wild type 
(GABPA +) versions (Fig. 5).
Discussion
Peto’s paradox raises intriguing questions which relate to both species and tumor cell evolution. Several 
mechanisms have been suggested to resolve the paradox, including inter-species differences in the number of 
tumor suppressor genes, rate of somatic cell turnover, cell size, efficiency of the immune system and replicative 
 senescence3,39–43. However, apart from mathematical  models44–46, there are limited research data available on 
the  topic47–52. Most of the hypotheses offered to resolve Peto’s paradox are based on comparisons made between 
organisms differing greatly in size, such as comparing whales or elephants with humans. In elephants, for exam-
ple, the solution for the paradox is in the different number of tumor suppressor genes. However, as DeGregori 
highlighted, there is no significant difference between human and mouse tumor suppressor mechanisms regard-
ing the number of tumor suppressor genes or even in the effectiveness of the immune  system41. Nevertheless, a 
mechanism that can explain the paradox in tumor frequency values between medium- and small-bodied animals 
should exist. Replicative senescence induced by telomere shortening is an evolved tumor suppressor mechanism 
in which small-bodied animals differ from medium-sized  ones53. With the work presented here we intended to 
seek an explanation for the mechanism of telomerase inactivation, which would also support the tumor sup-
pressor role of telomere shortening in large-bodied  rodents5,8. With our conclusions we do not question or wish 
to disregard other mechanisms that might also play a role in tumor suppression.
Studies on the evolution of telomerase agree that telomerase activation/reactivation in somatic cells has 
taken place several times during the evolution of  vertebrates6,7,22. According to the calculations of Gomes et al. 
the ancient placental mammalian telomerase was inactive in somatic cells and 5–7 independent events reacti-
vated it during the subsequent evolution of small mammalian  species22. These independent events suggest that 
Figure 2.  Distribution of transcription factor binding sites identified by in silico analysis within the − 1000 
to − 1 region upstream of the translation start in TERT promoters of 28 mammalian species. Green bars: 
distribution of the binding sites of the factor indicated on top of the plot at the 28 TERT promoter region. Yellow 
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telomerase expression could be beneficial in small animals. Telomerase is known to have other functions in 
addition to telomere  maintenance54, as it plays a role in protection against oxidative  stress55. Since small animals 
have higher metabolic rates, which increases oxidative stress, telomerase could be beneficial as part of the stress 
response mechanism. In larger-bodied relatives, however, telomerase expression could be unfavourable due to 
the necessity of stronger tumor suppression.
Telomerase is a multi-subunit complex; its activity in different placental mammals is determined primarily 
by the transcription of its catalytic subunit (TERT)31,56,57. TERT regulation is quite complex including regulation 
by transcription factors like the Myc/Max/Mad protein family and many others (Supplementary Fig S4.), miR-
NAs, alternative splicing, post translational modifications and subcellular trafficking—for reviews  see29,57–61. The 
lengths of telomeres in studied species correlate with telomerase expression  levels22, and several experiments have 
Figure 3.  ChIP-Seq data on GABP/GABPA binding to chromatin. (A) Publicly available ChIP-Seq data show 
modest GABPA binding on the TERT promoter of mouse and human embryonic stem cells. (B) No GABPA 
binding is seen on the TERT promoter in either somatic cells or in cancer cell lines without promoter mutation 
(MCF-7), but in cancer cell lines with TERT promoter mutations (SK-N-SH and HEPG2, C-124T) GABPA 
binding at the TERT promoter regions is clearly visible.
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demonstrated that telomere shortening happens due to the deletion or down-regulation of  TERT24,27. Sun et al. 
showed that the loss of one copy of TERT results in sufficient TERT down-regulation for replicative senescence 
to take place in  mice27. While enzyme evolution in general means changes in the protein sequence, in the case 
of telomerase the high frequency of activity changes in somatic cells and the fact that functional telomerase is 
essential in germ line and stem cells makes this mechanism unlikely, and justifies considering changes at tran-
scriptional level, as seen in other  examples62,63.
With this prerequisite, we assumed that molecular traces of TERT inactivation and reactivation have remained 
in the promoters of different species and consequently, comparison of the promoter sequences may unravel such 
traces. By comparing TERT promoters of 28 species, we found that multiple transcription factor binding motifs 
showed significant differences in active and inactive promoters, both in respect of their presence or absence and 
their pattern of location. GABPA (or NRF2), ELK1 and GATA3 transcription factors are more frequent in active 
promoters, while E47 (or TCF3) factor binding sites are more frequent in inactive promoters. As its binding 
sites showed the most significant differences between active and inactive promoters, we focused on the GABPA 
transcription factor. GABPA (NRF2) contributes to mitochondrial biogenesis as a regulator of mitochondrial 
Figure 4.  Detection of GABPA binding to mouse and beaver TERT promoters. (A) ChIP result indicates 
GABPA binding to TERT promoter and CoxVb promoter but not to intergenic region in mouse NIH 3T3 
fibroblast cells. NAC: no antibody control, TIC: total input control. The plot shows data from one out of three 
experiments with practically identical results. (B,C) Microscale thermophoresis (MST) plots indicate GFP-
GABPA binding to mutant beaver TERT promoter, but not to wild type beaver promoter. The plots resulted 
from experiments in which either (B) the GABPA protein was fluorescently labelled by GFP fusion, or (C) target 
DNA probes were fluorescently labelled. Standard deviation is calculated from results of technical replicates.
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 genes64. Surprisingly, under oxidative stress TERT is excluded from the nucleus and transferred to the mitochon-
dria where it plays a protective role against oxidative  stress55. This links TERT to the regulation of mitochondrial 
gene expression, and the common regulation strengthens our earlier proposal that active TERT in small animals 
is beneficial due to its role in oxidative stress reduction. GABPA sites were predicted in similar positions in dif-
ferent species, suggesting its conservation, while recognition sites of the other Ets family member, ELK1, were 
more dispersed (Fig. 2). A further reason that made the presence or lack of GABPA site fascinating was that de 
novo GABPA binding motifs that are responsible for telomerase reactivation in human tumors are frequently 
formed at 124 or 146 bp upstream of the START codon, in similar positions as those sites that we identified in 
our analysis. Telomerase activation is responsible for the immortalization of approximately 90% of tumor cells. 
The activation could happen in multiple ways, such as through epigenetic changes, alternative splicing, or by 
the previously mentioned TERT promoter mutation—for reviews  see31,61. In tumors the change in the − 124 or 
− 146 bp position in the promoter regions creates ETS factor recognition motifs. Although the ETS transcription 
factor family is large (28 members in  humans65), it was shown that GABPA selectively binds the de novo bind-
ing site and activates TERT  expression66,67. TERT promoter mutations in tumors are very  common56,68,69, and it 
is plausible that similar mutations could influence TERT expression during the evolution of rodents. Although 
GABPA activates TERT in tumors harbouring the promoter mutation, it should not be regarded exclusively as 
an oncogene. GABPA has tumor suppressor roles as well through the regulation of DICER1, which is responsible 
for multiple tumor suppressor mechanisms involving the miRNA  pathway70.
The ETS factor binding site that we identified as a GABPA binding site is missing in beavers, where telomer-
ase is inactivated. Thus, TERT inactivation in beavers could be explained with mutation(s) in a strong GABPA 
binding site. In the beaver promoter only weak motifs were predicted, while strong binding sites can be found 
in relatives such as in mice. The experiments performed to validate that GABPA indeed binds to the mice TERT 
promoter and not to that of beavers supported our assumption: GABPA was detected on the TERT promoter in 
mouse fibroblast cells, but we could not detect interaction between the transcription factor and beaver TERT 
promoter. The loss of GABPA binding site, however, does not necessarily mean decreased promoter activity, 
therefore we performed reporter assays where promoter regions with and without GABPA binding sites were 
tested. For these functional assays, human and beaver promoters were mutated to introduce GABPA binding 
motifs. The presence of the binding site increased promoter activity. In contrast, when mutations were intro-
duced to mouse and rat promoters to eliminate GABPA binding sites, the promoter activity was greatly reduced. 
Considering the experimental proof that links telomerase expression levels to telomere  length27 and telomere 
Figure 5.  The introduction of the GABPA binding site to human or beaver promoter increased TERT promoter 
activity, while mutation in the GABPA binding site in mouse or rat TERT promoter greatly decreased promoter 
activity. Cell lines used in the transient expression assays are indicated at the bottom.
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length to the widely accepted tumor suppressor mechanisms of replicative  senescence24, we conclude that our 
data support the initial hypothesis. Therefore, one could assume that in the beaver TERT promoter the loss of 
the GABPA binding motif reduced the promoter activity and inactivated TERT expression in somatic cells, by 
which replicative senescence was enabled. Since replicative senescence is a powerful tool to keep tumorigenesis 
at a low level, it is expected to allow beavers to develop larger body mass than other rodents.
It is important to emphasize that the hypothesis that the elimination of GABPA site(s) led to the loss of TERT 
promoter activity in somatic cells and by this generated replicative senescence as a tumor suppressor mechanism 
does not exclude the possibility that other effective tumor suppressor mechanisms are active in large-bodied 
animals. This could be the case in pigs (Sus scrofa) and camels (Camelus dromedarius), which also have GABPA 
sites in the TERT promoter and active  telomerase22,71.
It remains an open question whether apart from GABPA, any of the other sites we identified as being dif-
ferently represented between active and inactive TERT promoters determined TERT activity during evolution. 
The E47 helix-loop-helix transcription factor often forms heterodimers with other helix-loop-helix transcription 
factors like  MyoD72, a master regulator of muscle  development73. Indeed, alongside the E47 binding sites we also 
found significant difference in MyoD binding sites between active and inactive TERT promoters in our random 
sampling-bootstrap analysis (Supplementary Table S1). However, although the E47 and MyoD heterodimer is 
an activator of transcription, strong binding sites for them are present in inactive TERT promoters more fre-
quently than in active ones. Therefore, we do not presume that these elements play a role in telomerase silencing 
in somatic cells. However, they might have a role in maintaining sufficient telomerase expression in stem cells 
after the loss of ubiquitous expression of TERT.
The GATA3 transcription factor could also have a significant role in telomerase regulation, especially in 
group IV (Fig. 1A). Active telomerase and strong GATA3 binding motifs can be observed in polecats and bats, 
but also in the TERT promoter of camels and pigs, which are some of the rare exceptions of having active tel-
omerase despite large body size. These motifs are missing in sheep (Ovis aries) and rhinoceros (Ceratotherium 
simum sinum), which are their closest studied relatives (Fig. 1B)7,22. GATA3 expression levels are not uniform in 
all tissues; it has low expression levels in the brain, gut, liver and pancreas in humans and mice and expectedly 
in other mammals (Supplementary Table S4)74,75, therefore the absence or presence of GATA3 sites probably 
has no effect in these tissues. On the other hand, GATA3 expression levels are higher in fibroblasts from skin, 
kidney, lung or cornea, in which tissues telomerase activity was also tested and found  active22. Based on these 
observations a hypothesis can be formed that may explain the telomerase activity in bats, polecats, camels and 
pigs, which remains speculative until experimentally tested.
Materials and methods
Collection of data. TERT promoter and GABPA transcription factor sequences were downloaded from 
NCBI database. Identifiers are summarized in Supplementary Table S5. Data on telomerase activity in different 
species were obtained from the  literature6,7,22,32–34. 3D structure of GABPA DNA binding domain was recovered 
from PDB database (1AWC)76. ChIP-Seq data were obtained from available databases (Supplementary Table S6).
Bioinformatics. Transcription factor binding sites were determined by Match Publicversion 1.0 (TRANS-
FAC Public 7.0 ) and TFbind software (TRANSFAC R.3.4 database)35. Match uses Transfac database containing 
6133 factors. Transfac R.3.4 used by TFbind contains ~ 8000 binding sites. In humans, 1639 transcription factors 
are present from which 1107 have experimentally measured binding  sites77,78. Since both Match and TFbind use 
relatively old databases, after prediction we compared the results to known transcription factor binding sites on 
human  promoters29,57,58 (Supplementary Fig S4). Both Match and TFbind use manually set cut-off values to filter 
data. For our analysis, we set strict cut off values: in case of Match we used 1.0 core similarity and 0.94 overall 
matrices similarity; in case of TFbind 0.9 was set as cut off.
The number of samples we could use naturally was limited by the availability of data on TERT promoter 
sequences and telomerase activity among mammals. We therefore selected statistical methods suitable for small 
sample sizes to compare active and inactive promoters (Random sampling bootstrapping, Fisher’s exact test). For 
Random sampling bootstrapping we used R, while two tailed Fisher’s exact tests were done by GraphPad [https ://
www.graph pad.com/quick calcs /conti ngenc y1.cfm]. We used FIMO and Jaspar2020 database to calculate p-values 
for GABPA, Elk1, E47,GATA3 transcription factor binding sites identified by TFbind or Match (Supplementary 
Table S8)79. We also compared the methods of TF binding site prediction focusing on GABPA (Supplementary 
Fig S5). K-means clustering was done in Python3.6.3 using the KMeans algorithm from the scikit-learn library. 
To visualize GABPA 3D structure, UCSF Chimera was  used80. Masses of the examined species were obtained 
from PanTHERIA  database81. Canis familiaris weight is between 1.36 (Pomeranian) and 104.32 kg (Mastiffs) 
according to the American Kennel Club [https ://www.akc.org/exper t-advic e/nutri tion/breed -weigh t-chart /]; 
we presented the mass of an average German shepherd. Mouse Tert promoter sequences were extracted from 
Mouse Genomes Project data [https ://www.sange r.ac.uk/scien ce/data/mouse -genom es-proje ct]82. Scripts used 
are available in Supplementary Note S1.
ChIP. Chromatin was cross-linked and nuclei were isolated using cell lysis buffer (5 mM PIPES pH 8.0, 85 mM 
KCl, 0.5% NP40, 1 × PIC). Nuclei were lysed in nuclear lysis buffer (50 mM TRIS–HCl pH 8.0, 10 mM EDTA 
pH 8.0, 0.8% SDS, 1 × PIC), and sonicated in Bioruptor sonicator. 20–30 μg of total chromatin diluted in dilu-
tion buffer (10 mM TRIS pH 8.0, 0.5 mM EGTA pH 8.0, 1% Triton X-100, 140 mM NaCl, 1 × PIC) to 500 μl was 
used for each sample. Antibody (Ab) and no antibody (NAC) samples were pre-cleared with Dynabeads M-280 
Sheep Anti-Rabbit IgG (Thermo Fisher Scientific, Waltham, Massachusetts, USA). 5  μg of primary GABPA 
Antibody (GABPA Polyclonal Antibody, Thermo Fisher Scientific, AB_2545211) was used in the Ab sample. 
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Following incubation (1 h 4 °C), 40 μl Dynabeads were added. In the total input control (TIC) no antibodies or 
magnetic beads were used. After incubation (2 h, 4 °C), washing steps were done using freshly prepared Low 
Salt Wash Buffer (0.1% SDS, 1% triton X-100, 2 mM EDTA, 20 mM Tris–HCl pH 8.0, 150 mM NaCl), High Salt 
Wash Buffer (0.1% SDS, 1% triton X-100, 2 mM EDTA, 20 mM Tris–HCl pH 8.0, 500 mM NaCl), LiCl Wash 
Buffer (0.25 M LiCl, 1% NP-40, 1% Sodium Deoxycholate, 1 mM EDTA, 10 mM Tris–HCl pH 8.0) and TE 
Buffer (10 mM Tris–HCl pH 8.0, 1 mM EDTA) at 4 °C. DNA was eluted with elution buffer (1% SDS, 100 nM 
NaHCO3). The eluted samples were reverse cross-linked, RNase and proteinase treated, and DNA was purified 
with phenol-chlorophorm-isoamylalcohol (25:24:1) extraction. The regions of interest were amplified with PCR. 
Primers are listed in Supplementary Table S7.
Cloning. Cloning was done by HiFi assembly (NEB, Ipswich, Massachusetts, US, E5520S). DNA fragments 
were amplified with Q5 polymerase (NEB, M0491S). The list of primer sequences used for cloning different 
desired fragments can be found in Supplementary Table S7. For reporter assay constructs pGL3b, for protein 
expression pET16b vectors were used as backbones. The mutant promoter sequences were produced by PCR 
mutagenesis and verified by Sanger sequencing. Primers are listed in Supplementary Table S7.
Protein production and purification. GABPA proteins were produced in the Six Pack E. coli cell  line83. 
Cells were suspended in buffer A (20 mM HEPES pH 8.0, 50 mM imidazole, 400 mM NaCl) supplemented with 
proteinase inhibitor cocktail (PIC), and sonicated. The cell extracts were loaded on Nickel-NTA agarose column 
(QiaGen, Hilden, Germany) and after washing, heterologous proteins were eluted in buffer B (20 mM HEPES 
pH 8.0, 250 mM imidazole, 400 mM NaCl). Samples were concentrated and the buffer was changed using Ami-
con ultra filter units (Merck, Darmstadt, Germany).
Microscale thermophoresis. This technique is suitable to detect macromolecule interactions based on the 
changes in thermophoretic properties of macromolecules. The assay requires the fluorescent labelling of one of 
the interacting partners. For this we used either GFP-GABPA or GrGreen DNA dye (Lab Supply Mall Inno Vita 
Inc. Beijing, China). 16 step dilution series were prepared using wild type and mutant beaver promoter frag-
ments from 3.36 mM and 4.3 mM starting concentrations, respectively. GFP-GABPA (20 nM concentration) and 
DNA samples were mixed and incubated at room temperature for 20 min. For the reciprocal experiment, wild 
type and mutant beaver TERT promoter DNA fragments dyed by GrGreen DNA dye and purified his-GABPA 
protein (in concentrations from 1,6 uM to 48,9 pM in a16 step dilution series) were mixed. The measurements 
were done in buffer containing 20 mM TRIS pH 8.0, 50 mM NaCl, 10% Glycerol, 0.05% NP40, in standard capil-
laries. The equipment used was Monolith NT 115 (Nanotemper, München, Germany).
Cell culture. The dexamethasone-resistant hepatoma rat cell line (D12) was isolated and described by Vene-
tianer et al.84,85. Cell lines NIH 3T3 and MCF-7 were obtained originally from ATCC (Manassas, Virginia, USA, 
CRL-1658, HTB-22). UACC-257 cell line is from cancer panel NCI-60. Each cell line was maintained and used 
in tissue culture laboratories regularly at our Department. Mycoplasma infection of the cell lines was tested 
regularly using MycoAlert Mycoplasma Detection Kit (Lonza, Basel, Switzerland, LT07-418) as described by the 
supplier. Each cell line used here was free of detectable mycoplasma infection at the time used in the experiments 
described here. Cell lines were grown in Ham’s F12 (D12), RPMI (MCF-7, UACC-257), and DMEM (NIH3T3) 
media, supplemented with 10% fetal bovine serum (5% for Ham’s F12), 2 mM of glutamine and antibiotics.
Reporter assays. D12, MCF-7, UACC-257 and NIH 3T3 cell lines used for transient transfection followed 
by luciferase reporter assay. Transfections were done using Turbofect reagent (Thermo Scientific). For this 
2.5 × 105 cells were seeded into 6 well cell culturing plates. 4 μg of plasmid DNA was measured to 400 μl of serum 
free media, then 6 μl of transfection reagent was added to the solution and mixed by pipetting. After 20 min of 
incubation at room temperature the mixture was pipetted on the cells. The plate was gently rocked to mix the 
solution. Cells were collected 24 h after transfection using cell scratchers. Luciferase expression levels were deter-
mined using Luciferase Assay system (Promega, Madison, WI USA) as has been  described85. The measurements 
were performed in Orion L type Microplate Luminometer (Berthold Detection System, Simplicity 4.2 software). 
The protein concentrations were determined by Bradford reaction and the measured expression values were 
normalized using this data.
All experiments were conducted in at least 3 biological replicates. Outliers within these experiments were 
not excluded.
Data availability
Data analysed during this study are included in this published article (and its supplementary information files). 
The datasets used and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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